Economic comparison of diagnostic antibody production in perfusion stirred tank and in hollow fiber bioreactor processes

Biotechnology Progress

Volumn 27, Issue 6, 2011, Pages 1588-1598

  Vermasvuori, Raisa ^a   Hurme, Markku ^a  

^a AALTO UNIVERSITY   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY PRODUCTION; COST ITEMS; ECONOMIC COMPARISONS; HOLLOW FIBER BIOREACTOR; INVESTMENT COSTS; MONOCLONAL ANTIBODY PRODUCTION; PROTEIN A CHROMATOGRAPHY; STIRRED TANK; TOTAL COSTS;

BIOCONVERSION; BIOREACTORS; INVESTMENTS; MONOCLONAL ANTIBODIES; SPINNING (FIBERS); TANKS (CONTAINERS);

OPERATING COSTS;

DIAGNOSTIC AGENT; MONOCLONAL ANTIBODY;

ARTICLE; BATCH CELL CULTURE; BIOREACTOR; BIOTECHNOLOGY; COMPARATIVE STUDY; ECONOMICS; HUMAN; HYBRIDOMA; INSTRUMENTATION; METABOLISM; METHODOLOGY;

ANTIBODIES, MONOCLONAL; BATCH CELL CULTURE TECHNIQUES; BIOREACTORS; BIOTECHNOLOGY; HUMANS; HYBRIDOMAS;

EID: 82955233558     PISSN: 87567938     EISSN: 15206033     Source Type: Journal    
DOI: 10.1002/btpr.676     Document Type: Article

References (50)

1. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol. 2010; 10: 301-316.
2. Chartrain M, Chu L. Development and production of commercial therapeutic monoclonal antibodies in mammalian cell expression systems: an overview of the current upstream technologies. Curr Pharm Biotechnol. 2008; 9: 447-467.
3. Reichert JM. Monoclonal antibodies as innovative therapeutics. Curr Pharm Biotechnol. 2008; 9: 423-430.
4. Johansson DX, Drakenberg K, Hopmann KH, Schmidt A, Yari F, Hinkula J, Persson MAA. Efficient expression of recombinant human monoclonal antibodies in Drosophila S2 cells. J Immunol Methods. 2007; 318: 37-46.
5. Wattam T. ABI8200 Cellular detection system integration into the hybridoma generation process. Hum Antibodies. 2007; 16: 37- 42.
6. Roque ACA, Lowe CR, Taipa MA. Antibodies and genetically engineered related molecules: production and urification. Biotechnol Prog. 2004; 20: 639-654.
7. Carson KL. Flexibility-the guiding principle for antibody manufacturing. Nat Biotechol. 2005; 23: 1054-1058.
8. Rodrigues ME, Costa AR, Henriques M, Azeredo J, Oliveira R. Technological progresses in monoclonal antibody production systems. Biotechnol Prog. 2010; 26: 332-351.
9. Chu L, Robinson DK. Industrial choices for protein production by large-scale cell culture. Curr Opin Biotechnol. 2001; 12: 180-187.
10. Davis JM. Hollow fiber cell culture. In: Pörtner R, editor. Animal Cell Biotechnology-Methods and Protocols. Totowa, NJ: Humana Press; 2007: 337-352.
11. Yang ST, Luo J, Chen C. A fibrous-bed bioreactor for continuous production of monoclonal antibody by hybridoma. Adv Biochem Eng Biotechnol. 2004; 87: 61-96.
12. Castillo FJ. Hybridoma, Antibody production. In: Flickinger MC, Drew SW, editors. Encyclopedia of Bioprocess Technology-Fermentation, Biocatalysis, and Bioseparation. New York: Wiley; 2003: 1405-1418.
13. Farid SS. Established bioprocesses for producing antibodies as a basis for future planning. Adv Biochem Eng Biotechnol. 2006; 101: 1-42.
14. Walsh G. Biopharmaceutical benchmarks 2006. Nat Biotechnol. 2006; 24: 769-776.
15. Heine H, Biselli M, Wandrey C. High cell density cultivation of hybridoma cells: spin filter vs. immobilized culture. In: Bernard A, Griffiths B, Noé W, Wurm F, editors. Animal Cell Technology: Products from Cells, Cells as Products. Dordrecht, The Netherlands: Springer; 2000: 83-85.
16. Castilho LR, Medronho RA. Cell retention devices for suspended-cell perfusion cultures. Adv Biochem Eng Biotechnol. 2002; 74: 129-169.
17. Voisard D, Meuwly F, Ruffieux P-A, Baer G, Kadouri A. Potential of cell retention techniques for large-scale high-density perfusion culture of suspended mammalian cells. Biotechnol Bioeng. 2003; 82: 751-765.
18. Datar RV, Cartwright T, Rosen C. Process economics of animal cell and bacterial fermentations: a case study analysis of tissue plasminogen activator. Nat Biotech. 1993; 11: 349-357.
19. Vermasvuori R, Koskinen J, Salonen K, Sirén N, Weegar J, Dahlbacka J, Kalkkinen N, Weymarn Nv. Production of recombinant HIV-1 nef protein using different expression host systems: a techno-economical comparison. Biotechnol Prog. 2009; 25: 95-102.
20. Birch JR, Racher AJ. Antibody production. Adv Drug Deliv Rev. 2006; 58: 671-685.
21. Farid SS. Process economics of industrial monoclonal antibody manufacture. J Chromatogr B: Anal Technol Biomed Life Sci. 2007; 848: 8-18.
22. Werner RG. Economic aspects of commercial manufacture of biopharmaceuticals. J Biotechnol. 2004; 113: 171-182.
23. Lim AC, Washbrook J, Titchener-Hooker NJ, Farid SS. A computer-aided approach to compare the production economics of fed-batch and perfusion culture under uncertainty. Biotechnol Bioeng. 2006; 93: 687-697.
24. Rouf SA, Moo-Young M, Scharer JM, Douglas PL. Single versus multiple bioreactor scale-up: economy for high-value products. Biochem Eng J. 2000; 6: 25-31.
25. Farid SS, Washbrook J, Titchener-Hooker NJ. Decision-support tool for assessing biomanufacturing strategies under uncertainty: stainless steel versus disposable equipment for clinical trial material preparation. Biotechnol Prog. 2005; 21: 486-497.
26. Farid SS, Washbrook J, Titchener-Hooker NJ. Combining multiple quantitative and qualitative goals when assessing biomanufacturing strategies under uncertainty. Biotechnol Prog. 2005; 21: 1183-1191.
27. Novais JL, Titchener-Hooker NJ, Hoare M. Economic comparison between conventional and disposables-based technology for the production of biopharmaceuticals. Biotechnol Bioeng. 2001; 75: 143-153.
28. Werner RG. The development and production of biopharmaceuticals: technological and economic success factors. BioProcess Int. 2005; 3: 6-15.
29. Low D, O'Leary R, Pujar NS. Future of antibody purification. J Chromatogr B: Anal Technol Biomed Life Sci. 2007; 848: 48-63.
30. Gottschalk U. Bioseparation in antibody manufacturing: the good, the bad and the ugly. Biotechnol Prog. 2008; 24: 496-503.
31. Sommerfeld S, Strube J. Challenges in biotechnology production-generic processes and process optimization for monoclonal antibodies. Chem Eng Process. 2005; 44: 1123-1137.
32. Kretzmer G. Industrial processes with animal cells. Appl Microbiol Biotechnol. 2002; 59: 135-142.
33. Griffiths JB. Mammalian cell culture reactors, Scale up. In: Flickinger MC, Drew SW, editors. Encyclopedia of Bioprocess Technology-Fermentation, Biocatalysis, and Bioseparation. New York: Wiley; 2003: 1594-1607.
34. Guardia MJ, Hu W. Mammalian cell bioreactors. In: Flickinger MC, Drew SW, editors. Encyclopedia of Bioprocess Technology-Fermentation, Biocatalysis, and Bioseparation. New York: Wiley; 2003: 1587-1594.
35. Anonymous. Fibercell systems: hollow fiber cell culture bioreactor. Available at: Updated 2011; accessed 5.1.2011.
36. Deo YM, Mahadevan MD, Fuchs R. Practical considerations in operation and scale-up of spin-filter based bioreactors for monoclonal antibody production. Biotechnol Prog. 1996; 12: 57-64.
37. Andersen DC, Krummen L. Recombinant protein expression for therapeutic applications. Curr Opin Biotechnol. 2002; 13: 117-123.
38. Prashad M, Tarrach K. Depth filtration: cell clarification of bioreactor offloads. Filtration Sep. 2006; 43: 28-30.
39. Peters MS, Timmerhaus KD, West RE. Plant Design and Economics for Chemical Engineers, 5th Ed. Boston: McGraw-Hill; 2003.
40. Farid SS, Novais JL, Karri S, Washbrook J, Titchener-Hooker NJ. A tool for modeling strategic decisions in cell culture manufacturing. Biotechnol Prog. 2000; 16: 829-836.
41. Anonymous. ProSep® Ultra Plus Affinity Chromatography Media. Available at: Updated 2010; accessed 10.8.2010.
42. Lang HJ. Simplified approach to preliminary cost estimates. Chem Eng. 1948; 55: 112-113.
43. Sinnott RK. Coulson & Richardson's Chemical Engineering, 4th ed. Butterworth Heinemann: Oxford; 2005: 242-282.
44. Sinclair A, Monge M. Concept facility based on single-use systems, part 2: Leading the way for biomanufacturing in the 21st century. BioProcess Int. 2005; 3: 51-55.
45. Henzler H, Kauling DJ. Oxygenation of cell cultures. Bioprocess Biosyst Eng. 1993; 9: 61-75.
46. Farid SS, Washbrook J, Titchener-Hooker NJ. Modelling biopharmaceutical manufacture: design and implementation of SimBiopharma. Comput Chem Eng. 2007; 31: 1141-1158.
47. Jain E, Kumar A. Upstream processes in antibody production: evaluation of critical parameters. Biotechnol Adv. 2008; 26: 46-72.
48. Valdes R, Ibarra N, Gonzalez M, Alvarez T, Garcia J, Llambias R, Perez CA, Quintero O, Fischer R. CB.Hep-1 hybridoma growth and antibody production using protein-free medium in a hollow fiber bioreactor. Cytotechnology. 2001; 35: 145-154.
49. Yazaki PJ, Shively L, Clark C, Cheung C, Le W, Szpikowska B, Shively JE, Raubitschek AA, Wu AM. Mammalian expression and hollow fiber bioreactor production of recombinant anti-CEA diabody and minibody for clinical applications. J Immunol Methods. 2001; 253: 195-208.
50. Kelley B. Very large scale monoclonal antibody purification: the case for conventional unit operations. Biotechnol Prog. 2007; 23: 995-1008.